118 research outputs found

    Machine-learning-based high-benefit approach versus conventional high-risk approach in blood pressure management

    Get PDF
    高血圧診療における次世代の個別化医療戦略を提唱 --機械学習により個人の治療効果を予測する時代へ--. 京都大学プレスリリース. 2023-04-05.[Background] In medicine, clinicians treat individuals under an implicit assumption that high-risk patients would benefit most from the treatment (‘high-risk approach’). However, treating individuals with the highest estimated benefit using a novel machine-learning method (‘high-benefit approach’) may improve population health outcomes. [Methods] This study included 10 672 participants who were randomized to systolic blood pressure (SBP) target of either 0) versus the high-risk approach (treating individuals with SBP ≥130 mmHg). Using transportability formula, we also estimated the effect of these approaches among 14 575 US adults from National Health and Nutrition Examination Surveys (NHANES) 1999–2018. [Results] We found that 78.9% of individuals with SBP ≥130 mmHg benefited from the intensive SBP control. The high-benefit approach outperformed the high-risk approach [average treatment effect (95% CI), +9.36 (8.33–10.44) vs +1.65 (0.36–2.84) percentage point; difference between these two approaches, +7.71 (6.79–8.67) percentage points, P-value <0.001]. The results were consistent when we transported the results to the NHANES data. [Conclusions] The machine-learning-based high-benefit approach outperformed the high-risk approach with a larger treatment effect. These findings indicate that the high-benefit approach has the potential to maximize the effectiveness of treatment rather than the conventional high-risk approach, which needs to be validated in future research

    Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks With Health Outcomes Among Japanese Men

    Get PDF
    メタボ健診・特定保健指導制度の課題を提言 --エビデンスに基づく制度改善に期待--. 京都大学プレスリリース. 2020-10-09.Importance: Obesity and cardiovascular risks have become major public health problems. However, evidence is limited as to whether population-level lifestyle interventions for obesity and cardiovascular risk factors are associated with improved population health outcomes. Objective: To investigate the association of the national health guidance intervention in Japan with population health outcomes. Design, Setting, and Participants: This cohort study used a regression discontinuity design that included men aged 40 to 74 years who participated in the national health screening program in Japan from April 2013 to March 2018. Exposures: Assignment to the national health guidance intervention (counseling on healthy lifestyle and appropriate clinical follow-up for individuals found to have waist circumference of 85 cm or greater with 1 or more cardiovascular risk factors during annual national health screening program). Main Outcomes and Measures: Changes in obesity status (body weight, body mass index, waist circumference), and cardiovascular risk factors (blood pressure, hemoglobin A1c level, and low-density lipoprotein cholesterol level) 1 to 4 years after screening. Results: Of 74 693 men (mean [SD] age, 52.1 [7.8] years; mean [SD] baseline waist circumference, 86.3 [9.0] cm), the assignment to the health guidance intervention was associated with lower weight (adjusted difference, −0.29 kg; 95% CI, −0.50 to −0.08; P = .005), body mass index (−0.10; 95% CI, −0.17 to −0.03; P = .008), and waist circumference (−0.34 cm; 95% CI, −0.59 to −0.04; P = .02) 1 year after screening. The observed association of the guidance assignment attenuated over time and was no longer significant by years 3 to 4. No evidence was found that the health guidance intervention was associated with changes in participants’ systolic blood pressure, diastolic blood pressure, hemoglobin A1c level, or low-density lipoprotein cholesterol level in years 1 to 4. Conclusions and Relevance: Among working-age men in Japan, the national health guidance intervention was not associated with clinically meaningful weight loss or other cardiovascular risk factor reduction. Further research is warranted to understand the specific design of lifestyle interventions that are effective in improving obesity and cardiovascular risk factors

    Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study

    Get PDF
    [Objective] To determine changes in industry marketing payments to physicians due to the covid-19 pandemic. [Design] Quasi experimental, difference-in-difference study. [Data source] US nationwide database of licensed physicians, the National Plan and Provider Enumeration System, which was linked to a database of industry marketing payments made to physicians, Open Payments. [Population] All licensed US physicians from 2018 to 2020 and those who received payments from industry. [Main outcome measures] Changes in the value and the number of monthly industry payments physician received before (January-February 2020) and during the pandemic (April-December 2020) were assessed, adjusting for physicians’ characteristics (gender and specialty). As the control, data for the same months in 2019 were used. Industry payments by type of payments (eg, meals, travel, consulting fees, speaker compensation, honorariums), were also examined. [Results] Among 880 589 US physicians included in this study, 267 463 (30.4%) physicians received a total of 4 117 482 non-research payments with 626million(626 million (710 per physician; £610; €708) in 2020 (40-44% decrease from 1047min2018and1047m in 2018 and 1115m in 2019). Industry payments decreased significantly in the months of the covid-19 pandemic (adjusted change in the value of −48.4%; 95% confidence interval −50.6 to −46.2; P<0.001; and adjusted change in the number of −47.4%, 95% confidence interval −47.7 to −47.1; P<0.001), particularly for meals and travel fees. No evidence was seen of a decrease in the number of industry payments for consulting and honorariums. A similar pattern was observed across physicians’ gender and specialty. [Conclusions] Industry payments to physicians, particularly those involving physical interactions such as meals and travel, substantially decreased during the pandemic. How such changes affect prescription practices and the quality of clinical practice in the long term should be investigated

    Association of Daily Step Patterns With Mortality in US Adults

    Get PDF
    1週間の歩行パターンと死亡リスクの関連を明らかに --週2回しっかり歩くことで健康は維持できるか?--. 京都大学プレスリリース. 2023-03-30.[Importance] Previous studies have shown that individuals who regularly walk, particularly 8000 daily steps or more, experience lower mortality. However, little is known about the health benefits of walking intensively only a few days a week. [Objective] To evaluate the dose-response association between the number of days an individual takes 8000 steps or more and mortality among US adults. [Design, Setting, and Participants] This cohort study evaluated a representative sample of participants aged 20 years or older in the National Health and Nutrition Examination Surveys 2005-2006 who wore an accelerometer for 1 week and their mortality data through December 31, 2019. Data were analyzed from April 1, 2022, to January 31, 2023. [Exposures] Participants were grouped by the number of days per week they took 8000 steps or more (0 days, 1-2 days, and 3-7 days). [Main Outcomes and Measures] Multivariable ordinary least squares regression models were used to estimate adjusted risk differences (aRDs) for all-cause and cardiovascular mortality during the 10-year follow-up, adjusting for potential confounders (eg, age, sex, race and ethnicity, insurance status, marital status, smoking, comorbidities, and average daily step counts). [Results] Among 3101 participants (mean [SD] age, 50.5 [18.4] years; 1583 [51.0%] women and 1518 [49.0%] men; 666 [21.5%] Black, 734 [23.7%] Hispanic, 1579 [50.9%] White, and 122 [3.9%] other race and ethnicity), 632 (20.4%) did not take 8000 steps or more any day of the week, 532 (17.2%) took 8000 steps or more 1 to 2 days per week, and 1937 (62.5%) took 8000 steps or more 3 to 7 days per week. Over the 10-year follow-up, all-cause and cardiovascular deaths occurred in 439 (14.2%) and 148 (5.3%) participants, respectively. Compared with participants who walked 8000 steps or more 0 days per week, all-cause mortality risk was lower among those who took 8000 steps or more 1 to 2 days per week (aRD, −14.9%; 95% CI −18.8% to −10.9%) and 3 to 7 days per week (aRD, −16.5%; 95% CI, −20.4% to −12.5%). The dose-response association for both all-cause and cardiovascular mortality risk was curvilinear; the protective association plateaued at 3 days per week. Different thresholds for the number of daily steps between 6000 and 10 000 yielded similar results. [Conclusions and Relevance] In this cohort study of US adults, the number of days per week taking 8000 steps or more was associated with a lower risk of all-cause and cardiovascular mortality in a curvilinear fashion. These findings suggest that individuals may receive substantial health benefits by walking just a couple days a week
    corecore